OrbiMed’s Signify Health, Inc. SGFY Stock Holding History

OrbiMed’s Portfolio SGFY Stock Details SGFY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-900,000	Closed	-$12.4M	–	152
2022 Q2	$12.4M	Buy	900,000 +279,300	+45%	+$3.93M	0.23%	81
2022 Q1	$11.3M	Buy	+620,700	New	+$8.9M	0.18%	95
2021 Q2	–	Sell	-225,000	Closed	-$6.58M	–	180
2021 Q1	$6.58M	Buy	+225,000	New	+$6.96M	0.06%	134

Other funds holding SGFY

NMC

New Mountain Capital New York $139M AUM 26.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.75B AUM 102.57% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return

OrbiMed's SGFY Position: Q3 2022 in Review

OrbiMed sold out of Signify Health, Inc. (SGFY) in Q3 2022, closing a stake of 900,000 shares — an estimated $12.4M sold.

OrbiMed first reported a position in SGFY in Q1 2021 and held it in 3 quarters. The position peaked at $12.4M in Q2 2022. 204 funds tracked by Wall St. Rank hold SGFY as of Q3 2022.

OrbiMed reported no remaining Signify Health, Inc. position as of Q3 2022 after selling out during the quarter.
OrbiMed sold 900,000 Signify Health, Inc. shares in Q3 2022, an estimated $12.4M.
OrbiMed first reported a position in Signify Health, Inc. in Q1 2021 and held it in 3 quarters.
OrbiMed's Signify Health, Inc. position peaked at $12.4M in Q2 2022.
204 funds tracked by Wall St. Rank held Signify Health, Inc. as of Q3 2022.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.